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ABSTRACT 
The aim of the study is to investigate the effectiveness of cilostazol in 
patients with generalized atherosclerosis (GAS).  
A comprehensive examination of 65 male patients with proved GAS 
was performed (lesions of the lower extremities, carotid, mesenteric, 
coronary, cerebral arteries) and 28 healthy males (comparison group - 
CG) aged over 60 years. Patients with GAS consisted of 2 groups: 
GAS1 - patients in addition to basic therapy received cilostazol (C; 100 
mg 2 times per day); GAS2 - placebo. Patients with GAS showed a 
significant deterioration in blood flow (decrease in its volumetric blood 
flow - FV, increase in peak systolic velocity - PSV) in all studied 
arteries, episodes of myocardial ischemia according to daily ECG 
monitoring, decreased cognitive function (CF). In patients with GAS1 
on the background of taking C observed improvement (p<0,001) blood 
flow in the studied arteries (increase in FV and decrease in PSV), 
decrease in the number and duration of episodes of myocardial 
ischemia (p<0,01 and p<0,05, respectively), increase distances of 
painless and maximum walking distance (p<0,01), improvement of CF. 
The data obtained indicate the effectiveness of C as part of complex 
therapy in patients with GAS and expediency of further research in this 
direction to clarify the criteria for its appointment to such patients. 
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Introduction. Nowadays there are recommendations for the treatment of diseases caused by 
atherosclerotic lesions of individual vascular territories - coronary, cerebral, lower extremities and 
others. However, vascular damage by atherosclerosis has a systemic nature, resulting in often observed 
not only monofocal vascular damage, but the defeat of several vascular territories simultaneously. In 
WORLD SCIENCE                                                                                                                          ISSN 2413-1032 
 
RS Global                                                                                                            № 6(58), Vol.2, June 2020 21 
 
this case, we are talking about generalized atherosclerosis (GAS). Conducted by Z. Khoury and co-
authors more than 25 years ago, intravascular ultrasound investigation in most patients with 
atherosclerosis of the coronary arteries (according to coronary angiography) revealed the presence of 
atherosclerosis and other vessels - the aortic arch and descending aorta (81 and 91% of the aorta), 
femoralis arteries and carotid arteries (72 and 77%, respectively) [7]. These data have been confirmed 
by many other studies. GAS is especially common with the presence of clinical manifestations of 
chronic lower extremity ischemia - intermittent claudication syndrome (IC): according to the REACH 
register, signs of coronary heart disease (CHD) were observed in 57% of patients with lower extremity 
arterial disease (LEAD) and 90% of people with ICS. Among patients with LEAD, 60-80% of patients 
have hemodynamically significant lesions of coronary arteries, carotid arteries - 12-25% [8], according 
to the PARTNERS study, only 13% of patients with LEAD had no signs of CHD or cerebrovascular 
disease. These data indicated a significant prevalence of GAS. Moreover, GAS for a long time can be 
clinically manifested only for one of the vascular territories, and the lesions of other vessels have a 
subclinical course, which prevents its timely detection. However, atherosclerotic lesions of vessels of 
different territories are interconnected, which is confirmed by the presence of a positive relationship 
between the degree of ZANK and the frequency of strokes and transient ischemic attacks (TIA) [8]. 
The presence of GAS negatively affects the prognosis of patients. According to the Framingham 
study, vascular damage in several territories may be associated with a 2-3-fold increase in the risk of 
cerebral circulatory disorders in patients with CHD (20-60%), ischemic stroke (IS) (40%) and death 
from CHD (2-6 times) - in patients with LEAD, as well as high mortality from cardiovascular diseases 
caused by atherosclerosis, which, according to epidemiological studies, in Europe exceeds 4 million 
annually [8,9,13]. Significant deterioration of the prognosis of patients with GAS determines the 
importance of developing approaches to their treatment. 
In 2011, the European Society for Vascular Surgery (ESVS) together with the European 
Society of Cardiology (ESC) and the European Stroke Organization (ESO)developed, and in 2017 
supplemented, recommendations for the Diagnosis and Treatment of Peripheral Arterial Diseases, 
which include extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries 
[15]. These guidelines also include data on the examination and treatment of patients with vascular 
disease in two different territories. However, research on the treatment of patients with lesions of more 
than two vascular territories is insufficient. 
Till today many studies have proven the effectiveness of antiplatelet agents in the treatment of 
patients with cardiovascular disease associated with atherosclerosis of any vascular pool, and their 
complications, which led to inclusion these group of drugs to the appropriate local and international 
recommendations. Cilostazol occupies an important place in the treatment of patients with LEAD and 
ICS (level of evidence IA). Cilostazol (C) is a phosphodiesterase (PDE) inhibitor - selectively inhibits 
PDE type 3 in platelets, endothelial and smooth muscle cells. In Japan, C has been used since 1985. 
This drug has entered the clinical practice of America and Europe since the late 90s of the twentieth 
century - in 1999 the FDA, and in 2002 - the EMA (European Medicines Agency) officially allowed 
its use in patients with ICS. Today, C is considered the most effective drug in the treatment of patients 
with LEAD and ICS [1]. Clinical studies have also proven its effectiveness in the secondary 
prevention of stroke and TIA, reducing the incidence of restenosis after stenting of the arteries of the 
lower extremities, coronary and carotid arteries, as well as in patients with vasospastic angina 
[1,2,5,11,14]. The advantages of cilostazol compared to aspirin and other antiplatelet drugs in the 
development of bleeding have been proven [2,14]. 
The experiment on rats revealed an additional effect of C on the background of known effects 
- vasodilatation, anti-inflammatory and anti-apoptosis - significant antiulcer activity of the drug, 
comparable to the effect of ranitidine, but without antisecretory action [6]. 
It should be noted that most studies have analyzed the effectiveness of C in its effect on one of the 
vascular basins, mainly in the Asian patient population, as well as the risk of heart attack or stroke. The 
effectiveness of this drug in patients with GAS, especially the European population, needs further research. 
The aim of the study is to investigate the effectiveness of cilostazol in patients with 
generalized atherosclerosis. 
Materials and methods. The study included 65 patients with GAS and 28 healthy males 
(comparison group - CG) aged 60 years and older, who gave written consent to participate in this study. 
Patients with GAS were randomized into two groups - GAS1 and GAS2. The GAS1 group consisted of 
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32 patients with a mean age of 72.6 ± 4.4 years, the GAS2 group - 31 patients aged 71.5 ± 3.9 years. The 
mean age of GPs was 67.3 ± 3.5 years. All patients of groups GAS1 and GAS2 had LEAD with 
manifestations of ICS and signs of atherosclerotic lesions of the femoral artery or its branches, stable 
CHD, including myocardial infarction suffered 48% (15 of 32) patients GAS1 and 45% (14 of 31) 
GAS2, coronary revascularization - 71.9% (23 of 32) and 71% (22 of 31), respectively, the presence of a 
history of  IS - 46.9% (15 of 32) and 41.9% (13 of 31 ), TIA - 53.1% (17 of 32) and 61.3% (19 of 31); 
40.6% (13 of 32) and 39% (12 of 31) of patients with groups GAS1 and GAS2 had controlled arterial 
hypertension (AH), 28.1% of patients with compensated type 2 diabetes mellitus (9 of 32) and 32.3% (10 
of 31). Patients experienced cardiovascular complications more than six months before inclusion in the 
study. Patients with congestive heart failure, life-threatening arrhythmias, valvular heart disease less than 
six months before the start of the study cardiovascular complications, gastric and / or duodenal ulcers, 
persons at high risk of bleeding, including. h. thrombocytopenia, cancer, and other comorbidities 
requiring treatment were not included in the study. Basic treatment of patients with GAS was in 
accordance with existing guidelines and did not change during the study. 
Examination of patients included general clinical methods (anamnesis, analysis of the Rose 
questionnaire in the Edinburgh modification for ICS, determination of the severity of chronic ischemia 
of the lower extremities according to the Fontaine-Pokrovsky classification, objective examination, 
echocardiography and ECG at rest). All patients included in the study were determined ankle-brachial 
index (ABI), the value of which less than 0.9 is not only a sign of LEAD, but also associated with a 
significant deterioration in prognosis [4]. In the comparison group, the values of ABI were in the range 
of 1.09-1.30, in patients of the GAS group - in the range of 0.54-0.87. According to the generally 
accepted methods, Holter ECG monitoring (HM-ECG; Cardio Sens K "HAI-MEDICA", Ukraine) and 
vascular dopplerography (HITACHI, ALOKA, Arietta S70) were performed. The thickness of the 
intima-media complex (IMT), indicators of blood flow velocity - peak systolic volume (PSV) and 
volumetric blood flow velocity (FV), resistance index (RI) in the arteries of different territories - 
carotid (arteria carotis interna - ACI), mesenteric (arteria mesenterica superior - AMS), femoralis 
(arteria  femoralis communis - AFC), tibialis (arteria tibialis posterior - ATP). In addition, painless 
walking distance (PWD) and maximum walking distance (MWD) were assessed in patients in the 
GAS group. Cognitive function was investigated according to the Montreal Cognitive Function 
Assessment Scale (MoCA). 
Patients of the GAS1 group after the first examination in addition to the basic therapy were 
prescribed cilostazol ("plestazol" manufactured by the Kiev Vitamin Plant, which has certain 
compositional characteristics - patent №83911 from December 24, 2012 - additionally contains 
hypromylose, which promotes the gradual release of the active substance) 100 mg twice a day 30 
minutes before or 2 hours after meals. Only patients who took C for 12 weeks at a daily dose of 200 
mg were included in the GAS1 group in this analysis. Patients in the GAS2 group in addition to 
baseline therapy received placebo. Repeated comprehensive examination of patients with GAS was 
performed after twelve weeks of taking C or placebo. Patients in the comparison group were examined 
once. There were no signs of myocardial ischemia and clinically significant cardiac arrhythmias 
according to HM-ECG in CG. 
Statistical analysis was performed using the computer program SPSS, version 23. The nature 
of the distribution of variables was evaluated using the Kolmogorov-Smirnov test for one sample. The 
arithmetic mean (M) and the standard error (±m) were calculated for the normal distribution, and the 
median, lower and upper quartiles were calculated for the distribution different from the normal one. 
The reliability of the dynamics of the indicator was calculated by the method of pairwise variants. 
When comparing the values under the condition of normal data distribution, Student's t-test was used, 
while the Man-Whitney U-test was used when data distribution different from the normal one. The 
difference between the data was considered significant at p<0,05. 
Results and discussion. Patients in the GAS1, GAS2, and CG groups did not differ significantly 
in age. In all patients included in the study who had hypertension, on the background of basic treatment, 
blood pressure (BP; both systolic - SBP and diastolic - DBP) was within the target values; mean values of 
SBP/DBP between groups did not differ significantly (p>0.05), amounting to 128.0±2.7/80.2±2.5, 
132.1±3.1/76.3±2.8 and 130.5±2.9/76.8±2.7 mm Hg in groups CG, GAS1 and GAS2, respectively. 
Hemodynamically significant heart defects were not detected in the examined patients according to 
echocardiography, the values of the left ventricular ejection fraction were within normal values (>45%). 
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In 37.5% (12 of 32) patients of the GAS1 group and in 32.3% (10 of 31) of the GAS2 group who suffered 
from myocardial infarction, areas of hypokinesia were found, in 43.8% (14 of 32) of the GAS1 group and 
41.9% (13 of 31) of the GAS2 group - left ventricular hypertrophy (LV). An increase in the left 
ventricular myocardial mass index of more than 110 g/m2 was also found in 14.3% (4 out of 28) of CGs. 
The degree of vascular lesions of the lower extremities in patients with GAS groups differed, 
which led to heterogeneous clinical manifestations of ICS. All patients complained of pain in the calf 
muscles or together the calf and thigh muscles, arising during acceleration of the gait, lifting up or 
long gait at a normal pace. Pain in the lower extremities, which occurred during walking, was relieved 
within 2-10 minutes after stopping, also the patients had no pain during rest. The patients included in 
the study did not have trophic changes of the lower extremities. According to the Fontaine-Pokrovsky 
classification - Stage IIa had  37.5% (12 of 32) patients of the GAS1 group and 41.9% (13 of 31) 
patients of the GAS2 group (patients who before the onset of pain could walk a distance of 200 to 
1000 m), Stage IIb - 62.5% (20 of 32) and 58.1% (18 of 31) patients, respectively (in whom the 
walking distance to the onset of pain was less than 200m). 
The initial condition of the arteries and blood flow in the studied vessels in patients with 
GAS1 were significantly worse than in the comparison group (Table 1). It is known that the most 
informative indicator of the characteristics of the blood supply to the organs is the rate of volumetric 
blood flow. As can be seen from table 1, FV in all studied arteries in patients of the GAS1 group was 
significantly (p<0.001) lower than in individuals of CG. The decrease in FV was especially significant 
in a.tibialis posterior (by 4 times), which is expected due to the presence of ICS in patients with GAS. 
In a.femoralis communis FV was less by 2.8 times, in a.mesenterica superior – by 2.4 times, in 
a.carotis interna by 1.9 times. In the GAS2 group, the FV values did not differ from their values in the 
GAS1 group, it were: in a.tibialis posterior 4.0 (3.6-4.6) ml/min., in a.femoralis communis - 81.9 
(77.0-87.7) ml/min., in a.mesenterica superior - 72.7 (66.4-85.9)ml/min., in a. carotis interna - 130.8 
(126.1-136.8) ml/min. This confirms the presence in patients with GAS lesions of the studied vascular 
territories, with deterioration of blood supply relevant tissues and organs. The peak systolic velocity, 
on the other hand, was significantly higher (p<0.001) in patients of both groups with GAS compared 
with CG in all studied arteries. PSV values in groups GAS1 and GAS2 did not differ. 
Table 1. Initial indicators of blood flow in the patients of examination groups 
Measure- 
ments 
Аrteria carotis 
interna 
Arteria mesenterica 
superior 
Arteria femoralis 
communis 
Arteria tibialis 
posterior 
CG 
n=28 
GAS1 
n=32 
CG 
n=28 
GAS1 
n=32 
CG 
n=28 
GAS1 
n=32 
CG 
n=28 
GAS1 
n=32 
FV, 
ml/min 
249.3 
(135.1-
297.5) 
132.9 
(130.1-
137.0)*** 
178.3 
(170.1-
183.4) 
72.8 
(66.5-
86.5)*** 
217.1 
(156.4-
273.6) 
78.4 
(76.5-
85.2)*** 
15.3 
(10.1-
19,.9) 
3.8 
(3.5-
4.7)*** 
PSV, 
sm/sec 
74.4 
(72.9-
76.8) 
144.7 
(130.4-
168.3)*** 
57.1 
(54.9-
60.1) 
84.9 
(57.6-
93.7)*** 
70.8 
(68.3-
74.4) 
76.5 
(73.8-
84.3)*** 
78.9 
(69.1-
85.9) 
89.1 
(73.8-
92.2)** 
RІ, u.o. 0.85 
(0.77-
0.93) 
0.93 
(0.92-
0.99)* 
0.84 
(0.75-
0.94) 
0.97 
(0.84-
1.11)* 
0.91 
(0.82-
0.96) 
0.96 
(0.74-
0.96) 
0.89 
(0.79-
0.95) 
0.98 
(0.82-
1.12)* 
ІМC, 
mm 
0.96 
(0.94-
0.98) 
1.27 
(1.21-
1.32)*** 
0.97 
(0.93-
0.99) 
1.23 
(1.17-
1.28)*** 
0.99 
(0.98-
1.09) 
1.27 
(1.18-
1.40)*** 
0.99 
(0.97-
1.02) 
1.31 
(1.22-
1.40)*** 
Note. FV - volumetric blood flow; GAS - generalized atherosclerosis; IMT - an intima-media 
complex; MnV – mean average velocity; PSV - peak systolic velocity; RI - resistance index.  
The dynamics of the indicator is significant: *- p<0,05; **- p<0.01; ***- p<0.001 
 
It is known that the peak blood flow velocity in the vessel depends on the presence and 
severity of vasoconstriction, and the increase in PSV corresponds to the degree of vasoconstriction. At 
narrowing of vessels by 55-60% the peak systolic velocity can be both within norm, and exceed it, and 
at increase of a stenosis to 60-75% its accurate increase is observed. Regarding the determination of 
the level of carotid artery stenosis, according to the criteria of "consensus Panel Gray-Scale and 
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Doppler US Criteria for Diagnosis of ICA Stenosis" with stenosis less than 50% PSV in the internal 
carotid artery less than 125 sm/sec, with stenosis 50-69% - is in the range of 125-230 sm/sec, and with 
stenosis ≥70% exceeds 230 sm/sec. 
Thickening of intima-media complex of the studied arteries were observed in insignificant 
amount - from 14.3% (4 out of 28) to 25% (7 out of 28) in different vascular territories - in CG and in 
all patients with GAS. In addition, atherosclerotic plaques (1 to 3) were found in the femoral, tibial, 
and carotid arteries in all patients of the GAS1 and GAS2 groups. In 90.6% (29 out of 32) and in 
93.5% (29 out of 31) patients of the GAS1 and GAS2 groups, respectively, in the mesenteric arteries. 
Thus, the data of ultrasound confirmed the presence of atherosclerotic vascular lesions of the 
studied territories in patients with GAS. 
The average score on the Montreal MoCA scale, which characterizes the state of cognitive 
function, in patients with GAS was significantly (p<0.05) lower than in CG: in the groups GAS1 it 
was 19.93±0.97, in GAS2 – 19.35±0.67 and in CG - 23.11±0.72 points. Due to the fact that the groups 
did not differ significantly in age, this discrepancy can be attributed to the presence of atherosclerotic 
lesions of the carotid arteries that supply blood to the central nervous system (CNS) in patients with 
GAS, and cerebral complications - TIA and IS. 
Cilostazol in a daily dose of 200 mg was taken by 32 patients included in this analysis (group 
GAS1). It should be noted that initially C in this dose was prescribed to 37 patients, but in this analysis 
did not include 5 of these patients for the following reasons. In 2 of 37 patients (5.4%) on the 
background of taking C were recorded frequent ventricular arrhythmias, in connection with which C was 
canceled. In 3 of 37 patients (8.1%) taking C (200 mg/day) caused an increase in heart rate (HR) over 12 
beats/min and feeling the heartbeat, in this regard, the dose was halved (up to 100 mg/day). Other 
significant adverse effects which would require dose reduction or drug withdrawal was not recorded. 
However, in 4 of 32 (12.5%) patients of the GAS1 group there were adverse reactions that did not affect 
the subsequent intake of C: 9.4% (3 of 32) patients complained of moderate headache, 3.1% (1 out of 32) 
- dizziness, 6.25% (2 out of 32) noted a weakening of bowel movements within a few days. In 10 of 32 
patients (31.25%) there was a moderate increase in heart rate, which did not significantly affect the well-
being of patients. In the GAS2 group, 6.45% of patients (2 out of 31) complained of headache while 
taking placebo, 3.2% (1 of 31) of patients complained of a brief increase in dizziness, and 3.2% 
complained of nausea (1 of 31) patients. Heart rate did not change significantly in any of the patients 
from the GAS2 group. More frequent occurrence of side effects on the background of C and drug 
withdrawal in our study compared with the data of a multicenter study (8.1 and 1.7%, respectively) [3], 
which included patients with ICS, may be due to multifocal vascular lesions in our study. 
Against the background of taking cilostazol (in addition to basic therapy) 93.75% (30 of 32) 
patients of the GAS1 group noted a significant reduction in pain in the lower extremities, facilitating 
physical activity. This coincided with an increase in the painless walking distances and maximum 
walking, respectively, from (172.5±41.3) to (305.0±44.9)m (by 76.8%; p<0.01) and from (395,1±90.2) 
to (563.1±85.4)m (by 42.5%; p<0.01). The data is somewhat expected: most studies evaluating the 
effectiveness of C in patients with LEAD indicate an increase in walking distances against the 
background of its use [1,2,3,10]. In the GAS2 group, 16.1% (5 of 31) patients had a reduction in lower 
extremity pain during walking. But PWD and MWD on average in the group did not change 
significantly, at the first examination it was, respectively, 171.28±37.25 and 393.22±91.17m, at the 
second - 183.11±24.25 and 402.36±23.18m (p> 0.05 in both cases). 
Patients also reported a decrease in the number and intensity of episodes of pain in the chest and 
heart, which was confirmed by a decrease in the number of episodes of myocardial ischemia according to 
daily ECG monitoring. In the group GAS1 changes in the studied indicators under the influence of C were 
significant, in the group GAS2 the dynamics of HM-ECG was insignificant. Thus, in the group GAS1 the 
number of painful (PEMI) and painless episodes of myocardial ischemia (PlEMI) per day on the 
background of C decreased from 5.84±0.32 to 3.82±0.29 - by 34.6% (p<0.001) and from 8.15±0.68 to 
6.23±0.58 - by 23.6% (p<0.001). In the GAS2 group at the first and repeated examination, the daily amount 
of PEMI was 5.70±0.35 and 5.41±0.23, respectively; PlEMI - 8.11±0.67 and 7.62±0.31 (p>0.05 in both 
cases). Occurrence / increase in the number of ventricular arrhythmias (30-58 per day), found on re-
examination in 12.5% (4 of 32) patients of the GAS1 group, did not require discontinuation of the drug. 
Taking C during three months (200 mg/day) not only reduced the clinical manifestations of 
LEAD/ICS and coronary heart disease, but also significantly improved the blood supply of the studied 
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vascular territories, as evidenced by a significant increase in volumetric (p<0.001) blood flow velocity 
in the studied arteries. Thus, FV in ACI under the influence of treatment increased by 25.0±3.7 
ml/min., in AMS - by 12.9±1.8 ml/min., in AFC - by 14.9±1.9 ml/min, in ATP – by 2.6±0.3 ml/min. 
The peak systolic velocity decreased by 19.8±2.7 sm/sec in ACI (p<0.001), by 22.6±2.8 sm/sec in 
AMS (p<0.001), by 4.7±2.2 sm/sec in AFC (p<0.05), by 9.7±4.1 sm/sec in ATP (p<0.05). The 
thickness of IMT during this period on average in the group did not change significantly in any of the 
studied arteries, although in some cases there was a slight decrease in the indicator - by 0.01 mm. It 
may take longer, than three months, taking C to reduce vascular remodeling. Such data are available, 
Sung Hyuk Heo and co-authors found a significant reduction in the thickness intima-media complex of 
the carotid arteries with five years of C intake [12]. In patients of the GAS2 group, changes in blood 
flow parameters were smaller and multidirectional and, on average, no significant dynamics were 
found in the group (p>0.05). The increase in FV in ACI was by 9.8±8.1 ml/min., in AMS – by 2.1±1.8 
ml/min., in AFC - by 6.7±4.5 ml/min., in ATP - by 0.26±0.22 ml/min. Significant dynamics of PSV 
and IMT during this period were also not revealed. 
The majority of patients in the GAS1 group - 82.9% (29 out of 35) - noted a decrease in 
dizziness, especially when changing body position, and headache (although in 3 patients in this group, as 
mentioned above, C, on the contrary, caused a headache). Such positive dynamics may be associated 
with improved blood supply to the brain due to increased blood flow in the carotid arteries on the 
background of C. With the improvement of blood supply to the CNS and associated improvement of 
cognitive function on the background of C in patients with GAS1, not high but a significant (p<0.05) 
increase in MoCA - up to 20.97±0.59 points. In the GAS2 group, 19.4% (6 of 31) and 9.7% (3 of 31) of 
patients reported a reduction in headache and dizziness, respectively. The MoCA index on average in the 
group did not change (p>0.05), at re-examination it was 19.49±0.58 points. 
The obtained differences in the dynamics of the clinical condition and the studied parameters 
in the groups GAS1 and GAS2 indicate that the changes in the indicators in the group GAS1 are due 
to the influence of cilostazol. Improving blood flow, increasing walking distances, and reducing the 
number of episodes of myocardial ischemia under C is associated with its known effects of the 
selective PDE-3 inhibitor. Specifically, with a positive effect on endothelial function with increased 
release of nitric oxide, improved microcirculation, counteracting the proliferation of vascular smooth 
muscle cells, reducing signs of inflammation, oxidative stress and areas of ischemia, initiating 
neovascularization of ischemic extremities, provides a clinical effect. The reduction of restenosis after 
stenting of arteries with the use of C may also be of some importance [1,2,5]. 
Thus, the use of cilostazol in a daily dose of 200 mg on the background of basic therapy helps 
to improve the well-being and clinical condition of patients with generalized atherosclerosis - to 
improve exercise tolerance, increase walking distance, improving blood flow in atherosclerotic vessels 
and cognitive function, reducing the number and duration of episodes of myocardial ischemia. The 
data obtained indicate the feasibility of using cilostazol as part of complex therapy in patients with 
GAS and further research in this direction to clarify the criteria for its appointment to such patients. 
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